{
    "clinical_study": {
        "@rank": "125898", 
        "acronym": "PSC", 
        "arm_group": {
            "arm_group_label": "Xifaxan", 
            "arm_group_type": "Experimental", 
            "description": "Xifaxan 550 mg two times per day for three months"
        }, 
        "brief_summary": {
            "textblock": "In the current protocol, we propose the assessment of potential beneficial effects of the\n      antibiotic Xifaxan on liver biochemistries, liver related symptoms and Mayo risk score in 15\n      adult and 5 pediatric patients with PSC. Adult patients will receive Xifaxan, 550 mg twice\n      daily over a 12-week period. Pediatric patients with PSC whose weight is   greater than or\n      equal to 40 kg will receive Xifaxan, 550 mg twice daily."
        }, 
        "brief_title": "A Pilot Study of Xifaxan to Treat Patients With PSC", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Primary Sclerosing Cholangitis (PSC)", 
        "condition_browse": {
            "mesh_term": [
                "Cholangitis", 
                "Cholangitis, Sclerosing"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Diagnosis of PSC established by all of the following criteria:\n\n               -  Alkaline phosphatase >1.5 times upper limit of normal for at least 6 months\n                  duration\n\n               -  GGT >1.5 times upper limit of normal in pediatric patients\n\n               -  Cholangiography demonstrating intrahepatic and/or extrahepatic biliary\n                  obstruction, beading, or narrowing consistent with PSC\n\n               -  Liver histology in the past (if available for review) with features consistent\n                  with or diagnostic of PSC\n\n          -  Both genders\n\n          -  Adults:  Ages 18-75 years.\n\n          -  Pediatric:  Weight > 40 kg\n\n          -  Patient's informed consent for study participation\n\n        Exclusion criteria:\n\n          -  Treatment with systematic antibiotics, Azulfidine, ursodeoxycholic acid,\n             corticosteroids, colchicine, methotrexate, azathioprine, cyclosporine, chlorambucil,\n             budesonide, pentoxifylline, tacrolimus, vitamin E or prednisone in the preceding\n             three months\n\n          -  Active drug or alcohol use\n\n          -  Prior history of allergic reaction to the antibiotics which will be used in the study\n\n          -  Any condition that, in the opinion of the investigator, would interfere with the\n             patient's ability to complete the study safely or successfully\n\n          -  Evidence of decompensated liver disease such as recurrent variceal bleeding,\n             refractory ascites or spontaneous hepatic encephalopathy\n\n          -  Anticipated need for transplantation in one year (Mayo survival model <80% one-year\n             survival without transplant)\n\n          -  Findings highly suggestive of liver disease of other etiology such as chronic\n             alcoholic liver disease, chronic hepatitis B or C infection, hemochromatosis,\n             Wilson's disease,  1-antitrypsin deficiency, non-alcoholic steatohepatitis, primary\n             biliary cirrhosis or secondary sclerosing cholangitis\n\n          -  Treatment with any study medications in the preceding three months\n\n          -  Pregnancy or current lactation; subjects becoming pregnant during the study despite\n             all the precautions will be withdrawn and referred to their primary physicians"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01695174", 
            "org_study_id": "11-006516"
        }, 
        "intervention": {
            "arm_group_label": "Xifaxan", 
            "intervention_name": "Xifaxan", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Rifaximin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Primary Sclerosing Cholangitis", 
            "Xifaxan"
        ], 
        "lastchanged_date": "September 11, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic in Rochester"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Pilot Study of Xifaxan in Patients With Primary Sclerosing Cholangitis", 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Jayant Talwalkar, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "An improvement in elevated levels of alkaline phosphatase to less than half of the initial level at study entry", 
                "measure": "Improvement in alkaline phosphatase", 
                "safety_issue": "No", 
                "time_frame": "Three months"
            }, 
            {
                "description": "Absence of treatment failure which is defined as any of the following:  death, need for livertransplantation, side effects requiring discontinuation of therapy, worsening of liver biochemistries, voluntary discontinuation for any reason, marked worsening of fatigue or itching.", 
                "measure": "Absence of treatment failure", 
                "safety_issue": "Yes", 
                "time_frame": "Three months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01695174"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Jayant A. Talwalkar", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}